loading page

Yield improvement of enediyne yangpumicins in Micromonospora yangpuensis through ribosome engineering and fermentation optimization
  • +3
  • Zilong Wang,
  • Runze Sun,
  • Miao Li,
  • Ling Liu,
  • Yanwen Duan,
  • Yong Huang
Zilong Wang
Central South University

Corresponding Author:zilongwang@csu.edu.cn

Author Profile
Runze Sun
Central South University
Author Profile
Miao Li
Central South University
Author Profile
Ling Liu
Central South University
Author Profile
Yanwen Duan
Central South University
Author Profile
Yong Huang
Central South University
Author Profile


Yangpumicins (YPMs), eg. YPM A, F, and G, are newly discovered enediynes from Micromonospora yangpuensis DSM 45577, which could be exploited as promising payloads of antibody-drug conjugates. However, the low yield of YPMs in the wild-type strain (~1 mg/L) significantly hampers their further drug development. In this study, a combined ribosome engineering and fermentation optimization strategy has been used for yield improvement of YPMs. One gentamycin-resistant M. yangpuensis DSM 45577 strain (MY-G-1) showed higher YPMs production (7.4 ± 1.0 mg/L), while it exhibits delayed sporulation and slender mycelium under scanning electron microscopy. Whole genome re-sequencing of MY-G-1 reveals several deletion and single nucleotide polymorphism mutations, which were confirmed by PCR and DNA sequencing. Further Box–Behnken experiment and regression analysis determined that the optimal medium concentrations of soluble starch, mannitol, and pharmamedia for YPMs production in shaking flasks (10.0 ± 0.8 mg/L). Finally, the total titer of YPM A/F/G in MY-G-1 reached to 15.0 ± 2.5 mg/L in 3-L fermenters, which was about 11-fold higher than the original titer of 1.3 ± 0.3 mg/L in wild-type strain. Our study may be instrumental to develop YPMs into a clinical anticancer drug, and inspire the use of these multifaceted strategies for yield improvement in Micromonospora species.
13 May 2021Submitted to Biotechnology Journal
13 May 2021Submission Checks Completed
13 May 2021Assigned to Editor
24 May 2021Reviewer(s) Assigned
16 Jul 2021Editorial Decision: Revise Minor
30 Jul 20211st Revision Received
31 Jul 2021Assigned to Editor
31 Jul 2021Submission Checks Completed
31 Jul 2021Reviewer(s) Assigned
12 Aug 2021Editorial Decision: Revise Minor
19 Aug 20212nd Revision Received
20 Aug 2021Assigned to Editor
20 Aug 2021Submission Checks Completed
20 Aug 2021Reviewer(s) Assigned
20 Aug 2021Editorial Decision: Accept
Dec 2021Published in Biotechnology Journal volume 16 issue 12 on pages 2100250. 10.1002/biot.202100250